Reimbursement
By Chase Doyle
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) permanently eliminates the sustainable growth rate formula and provides annual payment adjustments through 2019. Although this law may ultimately stabilize Medicare physician reimbursement, oncologists are currently working to prepare for this long-term transition. Read More ›
Over the past several years, physician office–based infusion services have been migrating to the hospital outpatient setting. The 2 main reasons for this shift can be seen as (1) financial pressures that have made the private practice model increasingly difficult to sustain, and (2) hospitals generally enjoy better payment terms than private practices, and therefore generate higher margins, particularly for hospitals with access to the 340B drug pricing program. Read More ›
The sharply worded scuffle over the recent Centers for Medicare & Medicaid Services (CMS)’s proposed rule about Medicare Part B payments showcases some of the strong opposing forces at play in the increasingly costly US healthcare system, and the reason why it has been almost impossible to arrive at effective changes. Read More ›
This detailed article of codes related to colorectal cancer is intended to assist practice managers and other healthcare providers and payers to ensure their proper use of coding and billing information associated with the treatment of patients with colorectal cancer Read More ›
This detailed article of codes related to colorectal cancer is intended to assist practice managers and other healthcare providers and payers to ensure their proper use of coding and billing information associated with the treatment of patients with colorectal cancer. Read More ›
By Chase Doyle
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination. Read More ›
The date of the implementation of the International Classification of Diseases, Clinical Modification (ICD-10-CM, henceforth “ICD-10”), has come and gone, and we have survived what is arguably the most significant change for providers in the history of reporting healthcare services. Read More ›
By Corbin Davis
Given the high cost of care for acute leukemia, innovative payment strategies that reward longitudinal care and create economic incentives for data-driven care delivery are needed, according to Joseph Alvarnas, MD, Director of Value-Based Analytics, and Associate Clinical Professor of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA. Read More ›